FDA Approves Rezzayo for Candidemia and Invasive Candidiasis

The FDA has approved Cidara Therapeutics and Melinta Therapeutics’ once-weekly antifungal drug Rezzayo (rezafungin for injection) for treatment of adult patients with candidemia and invasive candidiasis with limited or no alternative treatment options.

The agency decision was supported by trial data showing the treatment’s noninferiority compared with the standard-of-care once-daily treatment caspofungin.

Rezzayo is the first new treatment option for the fungal infections in more than a decade.

Rezzayo is also being evaluated for prevention of invasive fungal diseases in adults undergoing allogeneic blood and marrow transplantation.